Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSMB5 | P28074 | 2/20 | 0.50 |
| ▸ | PSMB1 | P20618 | 2/20 | 0.50 |
| ▸ | CASP1 | P29466 | 3/20 | 0.45 |
| ▸ | CASP3 | P42574 | 12/20 | 0.45 |
| ▸ | CASP7 | P55210 | 1/20 | 0.43 |
| ▸ | CASP9 | P55211 | 1/20 | 0.43 |
| ▸ | CASP6 | P55212 | 1/20 | 0.43 |
| ▸ | CASP8 | Q14790 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL311997 | 0.86 | HDAC6 (0.47) | PSMB5PSMB1CASP1CASP3CASP7 | |
| SCHEMBL311998 | 0.84 | CASP1 (0.48) | CASP1CASP3CASP7CASP9CASP6 | |
| SCHEMBL311929 | 0.81 | NLRP3 (0.54) | PSMB5PSMB1CASP1KDM4E | |
| SCHEMBL311556 | 0.79 | CASP1 (0.48) | CASP1CASP3CASP7CASP9CASP6 | |
| SCHEMBL10044270 | 0.77 | KDM4E (0.55) | KDM4E | |
| SCHEMBL312168 | 0.77 | CASP1 (0.48) | CASP1CASP3CASP7CASP9CASP6 | |
| SCHEMBL312350 | 0.76 | CASP1 (0.43) | CASP1CASP3CASP7CASP9CASP6 | |
| SCHEMBL312351 | 0.76 | CASP1 (0.43) | CASP1CASP3CASP7CASP9CASP6 | |
| SCHEMBL10072700 | 0.76 | SMN1; SMN2 (0.55) | CASP1CASP3KDM4E | |
| SCHEMBL312082 | 0.75 | CASP3 (0.54) | CASP1CASP3CASP7CASP9CASP6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8288537-B2 | Caspase inhibitors and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-10-16 | — | — | US | disclosed |
| US-8288537-B2 | Caspase inhibitors and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-10-16 | — | — | US | disclosed |
| US-8288537-B2 | Caspase inhibitors and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-10-16 | — | — | US | disclosed |
| US-20120077830-A1 | CASPASE INHIBITORS AND USES THEREOF | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-03-29 | — | — | US | disclosed |
| US-20120077830-A1 | CASPASE INHIBITORS AND USES THEREOF | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-03-29 | — | — | US | disclosed |
| US-20120077830-A1 | CASPASE INHIBITORS AND USES THEREOF | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-03-29 | — | — | US | disclosed |
| US-8093392-B2 | Caspase inhibitors and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-01-10 | — | — | US | disclosed |
| US-8093392-B2 | Caspase inhibitors and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-01-10 | — | — | US | disclosed |
| US-8093392-B2 | Caspase inhibitors and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-01-10 | — | — | US | disclosed |
| US-20110130436-A1 | CASPASE INHIBITORS AND USES THEREOF | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-06-02 | — | — | US | disclosed |
| US-20090131456-A1 | CASPASE INHIBITORS AND USES THEREOF | VERTEX PHARMACEUTICALS INCORPORATED | 2009-05-21 | — | — | US | disclosed |
| US-20090131456-A1 | CASPASE INHIBITORS AND USES THEREOF | VERTEX PHARMACEUTICALS INCORPORATED | 2009-05-21 | — | — | US | disclosed |
| US-20090131456-A1 | CASPASE INHIBITORS AND USES THEREOF | VERTEX PHARMACEUTICALS INCORPORATED | 2009-05-21 | — | — | US | disclosed |
| US-7517987-B2 | Caspase inhibitors and uses thereof | VERTEX PHARMACEUTICAL INCORPORATED (US) | 2009-04-14 | — | — | US | disclosed |
| US-7517987-B2 | Caspase inhibitors and uses thereof | VERTEX PHARMACEUTICAL INCORPORATED (US) | 2009-04-14 | — | — | US | disclosed |
| US-7517987-B2 | Caspase inhibitors and uses thereof | VERTEX PHARMACEUTICAL INCORPORATED (US) | 2009-04-14 | — | — | US | disclosed |
| CN-101348455-A | Aspartic acid specificity cysteine proteinase inhibitors and uses thereof | VERTEX PHARMA (US) | 2009-01-21 | — | — | CN | disclosed |
| CN-100415718-C | Caspase inhibitors and uses thereof | VERTEX PHARMA (US) | 2008-09-03 | — | — | CN | disclosed |
| US-20030232846-A1 | Caspase inhibitors and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED | 2003-12-18 | — | — | US | disclosed |
| CN-1420872-A | Caspase inhibitors and uses thereof | VERTEX PHARMA (US) | 2003-05-28 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090131456-A1 | CASPASE INHIBITORS AND USES THEREOF | CASP1, CASP3, CASP2 | PSMB5 899/4885PSMB1 855/4885CASP1 1/4885 |
| US-20120077830-A1 | CASPASE INHIBITORS AND USES THEREOF | CASP1, CASP3, CASP2 | PSMB5 899/4885PSMB1 855/4885CASP1 1/4885 |
| US-20110130436-A1 | CASPASE INHIBITORS AND USES THEREOF | CASP1, CASP3, CASP2 | PSMB5 899/4885PSMB1 855/4885CASP1 1/4885 |
| US-20030232846-A1 | Caspase inhibitors and uses thereof | CASP1, CASP3, CASP2 | PSMB5 774/4885PSMB1 461/4885CASP1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.